An integrated genomic definition and therapeutic strategy for androgen-indifferent prostate cancers

Ended Project Grant Awarded Last action

Award ID
W81XWH2210258
Recipient
Awarding agency
Obligated
$2,172,614

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Funding
  • $1,086,307.00 Federal
  • $1,086,307.00 Non-federal
Place of performance
Houston, TX 77030, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The University of Texas MD Anderson Cancer Center will receive $2,172,614 under a three-year Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2022 to September 2025 to develop an integrated genomic and therapeutic strategy for androgen-indifferent prostate cancers. The Military Medical Research and Development program supports biomedical research with the goals of improving military and public health care through innovative clinical solutions. This award furthers those goals by investigating precision oncology approaches that may transform treatment for hard-to-treat forms of prostate cancer.

Quick answers

Who received award W81XWH2210258?

W81XWH2210258 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by Medical Command (Department of the Army) on September 30, 2022.

How much is award W81XWH2210258 worth?

$2,172,614 has been obligated on W81XWH2210258: $1,086,307 in federal funding and $1,086,307 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login